Serum Levels of Fetuin-A in Patients with Acne Vulgaris

Authors
Ahmed A. W. Saleh¹, Rehab M. Salem¹, Asmaa A. El-Fallah², Ahmad S. A.Wahab³*

Dermatology and Andrology¹, Clinical and Chemical Pathology², Departments¹, M.B.B.Ch. (Al-Mustansiriya University-Iraq)³, Faculty of Medicine, Benha University, Egypt
*Corresponding Author
Ahmad Shakib A.Wahab

Abstract
Background: Acne vulgaris is a common cutaneous disorder involving dysfunction of the pilo-sebaceous unit. Acne vulgaris affects up to 80% of Americans at some point in their lives. Though prevalent most frequently in adolescents, it may persist well into adulthood in some individuals.

Aim of Work: The aim of this study is to evaluate the serum levels of Fetuin-A in patients with acne vulgaris and to assess its relation to the clinical severity of disease.

Methods: This case-control study was conducted in Outpatient Clinic of Dermatology and Andrology, Department of Benha University. The study included 80 participants; 60 patients suffering from acne vulgaris, in addition to 20 apparently healthy, age and sex matched individuals as control group, serum level of fetuin A was be assessed in all participants.

Results: The result of the study revealed there was negative non-significant correlation between Serum Fetuin A and sex, course of disease, Stress, Sun Exposure, Relation to Smoking, Post Acne Scar, the age and GAGS score.

Conclusion: Serum fetuin-A levels are detected higher in patients with acne. Also, there are no statistically significant relation between it and gender, age, Duration of disease, course of disease and in terms of stress, Sun Exposure, Smoking, Post Acne Scar, Family History, Diet & PIH.

Keywords: Acne vulgaris, fetuin-A, case-control, Outpatient.

Introduction
Acne vulgaris is a common cutaneous disorder involving dysfunction of the pilosebaceous unit. Acne vulgaris affects up to 80% of Americans at some point in their lives. Though prevalent most frequently in adolescents, it may persist well into adulthood in some individuals(1).

The traditional paradigm of acne has generally consisted of four components, often presented in a sequential fashion. Androgen excess leads to increased sebum production, along with follicular hyperkeratinization which results in plugging of the follicle. This allows the bacterium Propionibacterium acnes to grow within the follicle, eventually culminating in an inflammatory cascade and clinically evident disease(2).

Serum Fetuin-A (also called α-2 heremanschmid glycoprotein) is a multifunctional glycoprotein predominantly secreted by the liver and mainly involved in promoting insulin resistance(3).

Accumulating experimental and epidemiological studies reported that it was associated with a spectrum of cardiometabolic disorders, such as

Ahmed A. W. Saleh et al JMSCR Volume 07 Issue 10 October 2019
metabolic syndrome, nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular diseases (CVD)\(^4\).

It has been currently recognized as one of the most significant hepatokines regulating human metabolism\(^5\).

Fetuin-A protein is Alpha 2-Heremans Schmid glycoprotein (AHSG) of 62 kilo Dalton (KD). It belongs to the class of cysteine proteinase inhibitors, which are responsible for bone resorption\(^6\).

It acts as a negative acute phase reactant synthesized by the liver cells, it is responsible for preventing calcium and phosphate precipitation in the blood by increasing their solubility and inhibiting calcium crystal growth\(^7\).

Fetuin-A is participating in macrophage deactivation by being as anti-inflammatory mediators\(^8\).

**Patients and Methods**

**Subjects:** This case-control study was conducted in Outpatient Clinic of Dermatology and Andrology, Department of Benha University. The study included 80 participants; 60 patients suffering from acne vulgaris, in addition to 20 apparently healthy, age and sex matched individuals as control group. A written informed consents were obtained from all participants. The study was approved by the Local Ethics Committee on Research involving human subjects of Benha Faculty of Medicine.

**Studied Groups**

**A. Patients Group:** included sixty patients with different presentations of acne vulgaris classified according to the global acne grading system (GAGS) into three groups:

a. **Group A:** 20 patients with mild acne vulgaris.

b. **Group B:** 20 patients with moderate acne vulgaris.

c. **Group C:** 20 patients with severe acne vulgaris.

**B. Control Subjects Group:** included twenty apparently healthy subjects of matched age and sex served as a control group.

**Exclusion Criteria:** Subjects with any of the following conditions were excluded from the study:

- Patients with infectious, inflammatory or autoimmune cutaneous or systemic diseases.
- Malignancy.
- Pregnancy and lactation.
- Patients with liver or kidney disease.

**Inclusion Criteria**

- Patients with acne vulgaris.
- Age between 12 and 25 years ago.

**I. Methods:** Patients under study were subjected to the following:

1. **Full History Taking Including**

   - Personal history, course and duration of acne vulgaris in the patients and various demographic and lifestyle factors were recorded, including age, gender, any relation to stress, sun exposure, smoking and diet.

   - Family history of acne vulgaris: family histories were obtained from all patients.

2. **General Examination:** Complete general examination was performed for all patients with emphasis on the Body Mass Index (BMI). The BMI is defined as the body mass (weight) divided by the square of the body height and is universally expressed in units of kg/m\(^2\), resulting from weight in kilograms and height in meters. BMI ranges are underweight: under 18.5, normal weight: 18.5 to 25, overweight: 25 to 30, obese: over 30

3. **Dermatological Clinical Examination:** The patients were examined carefully to detect acne lesions and to determine their types, distribution and grading. The grading of acne lesions was assessed according to the global acne grading system (GAGS)\(^9\).
Results

Sociodemographic Data
There was insignificant difference between patients and controls regarding age, BMI and sex, the mean age of cases was 18.833±2.924 versus 19.350± 3.438 in control, with BMI 24.637± 4.005 in cases versus 25.570±4.560 in control group. The majority was female 90 % & 80% in cases and control group respectively. There was insignificant difference between patients and controls regarding age, BMI and sex (p= 0.515, 0.386 and 0.242 respectively) (Table 2).

Table 1: Sociodemographic data of the studied groups

| Groups       | Patients | Controls | T-Test or Chi-square |
|--------------|----------|----------|----------------------|
| Age Range    | 13 - 24  | 15 - 25  | -0.655               |
| Mean ±SD     | 18.833 ± 2.924 | 19.350 ± 3.438 | 0.515               |
| BMI Range    | 16.33 - 34.51 | 18.02 - 33.59 | -0.871               |
| Mean ±SD     | 24.637 ± 4.005 | 25.570 ± 4.560 | 0.386               |
| Sex Male     | 6 - 10.00 | 4 - 20.00 | 1.371               |
| Female       | 54 - 90.00 | 16 - 80.00 | 0.242               |

Table 2: History findings in the patients group

| History Parameters | N  | %   |
|--------------------|----|-----|
| Course             |    |     |
| Progressive        | 15 | 25.00 |
| Stationary         | 45 | 75.00 |
| Positive Family History | 33 | 55.00 |
| Positive Relation To Stress | 40 | 66.67 |
| Positive Relation To Sun Exposure | 56 | 93.33 |
| Positive Relation To Smoking | 8  | 13.33 |
| Positive Relation To Diet | 52 | 86.67 |

Table 3: Clinical findings in the patients group

| Clinical aspects          | N     | %   |
|---------------------------|-------|-----|
| GAGS. (Mean± SD)          | 21.950± 8.903 |     |
| Positive Post Acne Scar   | 23    | 38.33 |
| Positive PIH              | 56    | 93.33 |

The mean value of global acne grading system (GAGS) was 21.950± 8.903.
In current study, 93.33% of cases had post inflammatory hyperpigmentation and 38.33 % had Positive Post Acne Scar.

Laboratory Investigations
The mean serum level of fetuin A in patients group (164.485±91.432) was significantly higher than that in the control group (109.381±40.127) as p=0.011.

93.33% had positive relation to sun exposure, 13.33% with positive relation to smoking and 86.67 with positive relation to diet.

GAGS: global acne grading system, SD: standard deviation, PIH: post inflammatory hyperpigmentation.

Fig 1: Serum levels of fetuin A in the studied groups
Table 4: Relation between serum fetuin A and studied variables

|                      | Serum Fetuin A | T-Test         |
|----------------------|----------------|----------------|
|                      | N  | Mean ± SD | T  | P-value |
| Sex                  |    |           |    |         |
| Male                 | 6  | 144.658 ± 34.443 | -0.557 | 0.580 |
| Female               | 54 | 166.688 ± 95.629 | -0.344 | 0.732 |
| Course               |    |           |    |         |
| Progressive          | 15 | 157.391 ± 41.014 | -0.513 | 0.607 |
| Stationary           | 45 | 166.849 ± 103.207 | -0.129 | 0.268 |
| Family History       |    |           |    |         |
| Positive             | 33 | 176.141 ± 114.650 | 1.094 | 0.279 |
| Negative             | 27 | 150.238 ± 49.086 | -0.340 | 0.732 |
| Relation To Stress   |    |           |    |         |
| Positive             | 40 | 151.359 ± 45.052 | -1.593 | 0.117 |
| Negative             | 20 | 190.737 ± 143.894 | -0.340 | 0.732 |
| Relation To Sun Exposure | 56 | 160.717 ± 93.263 | -1.199 | 0.235 |
| Negative             | 4  | 217.238 ± 31.209 | -0.788 | 0.434 |
| Relation To Smoking  |    |           |    |         |
| Positive             | 8  | 140.684 ± 42.012 | -0.788 | 0.434 |
| Negative             | 52 | 168.146 ± 96.574 | -0.851 | 0.397 |
| Relation To Diet     |    |           |    |         |
| Positive             | 52 | 168.447 ± 95.091 | 0.851 | 0.397 |
| Negative             | 8  | 138.729 ± 60.894 | 0.851 | 0.397 |
| Post Acne Scar       |    |           |    |         |
| Positive             | 23 | 146.359 ± 38.249 | -1.216 | 0.229 |
| Negative             | 37 | 175.752 ± 111.653 | -1.216 | 0.229 |
| PIH                  |    |           |    |         |
| Positive             | 56 | 165.217 ± 93.421 | 0.230 | 0.819 |
| Negative             | 4  | 154.235 ± 65.240 | 0.230 | 0.819 |

PIH: post inflammatory hyperpigmentation, P<0.05 is significant, SD: standard deviation, Fetuin A.

As shown in this table, there was negative non-significant correlation between Serum Fetuin A and sex, course of disease, Stress, Sun Exposure, Relation to Smoking, Post Acne Scar, the age and GAGS score.

On the other hand, there was positive non-significant correlation between Serum Fetuin A and Family History (r=1.094 & p=0.279), Relation to Diet (r=0.854 & p=0.397), PIH (r=0.230 & p=0.819), BMI (r=0.123 & p=0.351) and Duration of acne (r=0.159 & p=0.224), and shown in the below graph.

Table 5: Correlation between serum fetuin A and studied variables.

|                      | Serum Fetuin A | P-value |
|----------------------|----------------|---------|
|                      | r             |         |
| Age                  | -0.024        | 0.857   |
| BMI                  | 0.123         | 0.351   |
| GAGS.                | -0.158        | 0.228   |

BMI: body mass index, P<0.05 is significant, GAGS: global acne grading system.

Table 6

|                      | ROC curve between Patients and Controls |
|----------------------|----------------------------------------|
|                      | Cutoff  | Sensitivity | Specificity | PPV  | NPV  | Accuracy |
| Serum Fetuin A       | >138.57 | 68.33       | 80.00       | 91.1 | 45.7 | 77.2%     |

ROC: receiver operating characteristic, PPV: positive predictive value, NPV: negative predictive value.

In current study, at cut off >138.57 ng/ml, serum fetuin A had 68.33% sensitivity and 80% specificity for discrimination between Patients and Controls with 91.1% PPV, 45.7% NPV and 77.2% Accuracy.

Discussion

Acne is a chronic dermatosis that affects the pilosebaceous follicles. The physiopathogenesis of this condition involves periglandular dermal inflammation mechanisms, sebum hyperproduction, follicular hyperkeratosis, an
increase of colonization of Propionibacterium acnes (\textit{P. acnes}), and hormones\textsuperscript{(10)}. It was observed that many of these pathogenic mechanisms are governed by a bio-immuno-molecular phenomena that serves as the basis for research on and the future development of possible individual treatments for this dermatosis.\textsuperscript{(11)}

Fetuin-A is a glycoprotein produced primarily in the liver and secreted into circulation in high concentrations in humans with fatty liver disease; it binds the insulin receptor and inhibits hepatic and muscle insulin signaling resulting in insulin resistance. In humans, high levels of fetuin-A have been associated with greater risks for type 2 diabetes (T2D) and with features of the metabolic syndrome; paradoxically, increased fetuin-A concentrations prevent vascular calcification and exert a protective role in systemic inflammation, suggesting that fetuin-A secretion can be divergently regulated in different pathological conditions\textsuperscript{(12)}.

The aim of this study was to evaluate the serum levels of fetuin-A in 60 patients with acne vulgaris and 20 apparently healthy age/sex and BMI matched persons as a control subjects group and to assess its relation to the clinical severity of disease.

To the best of our knowledge, this is the first study to compare fetuin-A levels in fetuin A in pathogenesis of acne. In current study, the mean serum level of fetuin A in patients group (164.485±91.432) was significantly higher than that in the control group (109.381±40.127) as p=0.011. This elevation may be explained by absence of active infection or inflammation in our cases as all patients with acne usually received multiple treatment line and in our study we don’t documented the used treatment and time science last dose of it. There was debate about its role in inflammation and clear role in inflammatory disease still matter of debate

Despite its abundance, the functions of fetuin-A remain poorly understood. A wide range of biological functions have been proposed for fetuin-A based on its structural similarities to other proteins or physical interactions with biogenic molecules.

**Fetuin-A in inflammation**

Acute phase response: Fetuin-A had early had been described as an anti-acute phase protein in sepsis, yet it can act as a positive or negative acute phase protein depending on the respective stimulus\textsuperscript{(13)}: early proinflammatory mediators (TNF-alpha, IL-1, IL-6, Interferon-gamma) down regulate fetuin-A, thus allowing for a strong inflammatory response and excess accumulation of late mediators (e.g., High-Mobility-Group-Protein B1, HMGB1); late pro-inflammatory mediators (such as HMGB1) stimulate hepatic fetuin-A expression, thereby restoring circulating fetuin-A levels in late stages of sepsis\textsuperscript{(14)}.

Seemingly, the mode of inflammation (infection or injury) may contribute to the ensuing (positive or negative) acute phase reactions and effects of fetuin-A. Fetuin is a prerequisite of anti-inflammatory protective actions of cationic polyamines (e.g., spermine)\textsuperscript{(15)}.

**Fetuin-A as an anti-inflammatory protein**

For instance, fetuin-A shares amino acid sequence homology to type II anti-inflammatory cytokines (TGF-\(\beta\)) receptors\textsuperscript{(16)} , and has been proposed as an inhibitor of the TGF-\(\beta\) signaling pathway. Similarly, fetuin-A exhibits amino acid sequence similarity to insulin receptor tyrosine kinases\textsuperscript{(17)}, and can bind to the insulin receptor, thereby inactivating (rather than activating, as in the case for insulin) the receptor tyrosine kinase\textsuperscript{(18)}.

This may partly explain why higher fetuin-A levels were associated with insulin resistance in some patients with type 2 diabetes\textsuperscript{(19)}.

As a glycoprotein, fetuin-A carries two N-linked and three O-linked oligosaccharide chains that terminate with sialic acid residues, enabling the binding of cationic Ca\(^{2+}\) ions. Accordingly, fetuin-A has been proposed as an endogenous inhibitor of pathological mineralization or calcification in soft tissues\textsuperscript{(20)}. 

Ahmed A. W. Saleh et al JMSCR Volume 07 Issue 10 October 2019
Specifically, fetuin-A forms protein-mineral colloids with calcium and phosphate (Jahn-Dechent et al., 2011), thereby preventing uncontrolled mineralization that may otherwise occur under pathological conditions (21).

As aforementioned, fetuin-A also functions as an opsonin for cationic spermine, and its availability to immune cells may be critical for regulating the innate immune response (22).

Indeed, levels of fetuin-A in macrophage cultures was decreased by 40% after stimulation with LPS (100 ng/ml, 2 h). Supplementation of LPS-stimulated macrophages with fetuin-A (100 μg/ml) conversely elevated cellular fetuin-A levels by 30–50% (23), confirming the notion that macrophages can ‘adopt’ fetuin-A from the environment (22).

Intriguingly, exogenously administered fetuin-A was predominantly localized in LC3-containing cytoplasmic vesicles - possibly autophagosomes or amphisomes - in LPS-stimulated macrophages (23).

At higher concentrations (e.g., 3.5 mg/ml), even crude fetuin-A (> 98%) can almost completely abrogated endotoxin-induced release of IL-1 and nitric oxide in macrophage cultures (24).

Following gel filtration and ion-exchange chromatography, the highly purified fetuin-A almost completely abrogated proinflammatory mediators (e.g., TNF, IFN-γ, and HMGB1) or LPS-induced HMGB1 release even when given at relative lower doses (e.g., 100 μg/ml), suggesting fetuin-A as an effective anti-inflammatory APP (15).

So we depends on other studies evaluated the level of fetuin in many disease. For example.

Psoriasis (25) Reported that serum fetuin A levels were elevated in patients with psoriasis in comparison with the healthy individuals.

In disagreement with current results (26) found significant decreased fetuin A levels in all patients with psoriasis compared to controls. They suggest that inflammation may cause this reduction because fetuin A as it was known as a negative acute phase protein.

In study by (27) The mean serum fetuin-A level was 12.0 ± 2.2 ng/ml in the psoriasis group and 14.6 ± 2.4 ng/ml in the healthy control group, and this difference was significant (p < 0.001) which in contrast to our observation. Probably, these discrepancies may be related to differences in level of insulin resistance and other yet undefined metabolic factors.

Psoriasis arthiritis (SpA)

In (28) study, the serum fetuin-A levels were lower in psoriasis arthiritis (SpA) patients than in controls. Additionally, compared to controls, SpA patients had an increased risk of decreased serum fetuin-A levels.

And their explanation because the serum fetuin-A is regulated as a negative acute phase protein (anti-inflammatory) and its serum concentration falls during the acute inflammatory response and normalizes when the infection is successfully treated (13).

Polycystic ovary syndrome

In the paper by (29) mean serum fetuin-A concentrations were considerably elevated in polycystic ovary syndrome compared to healthy controls.

But (30) finding of lower levels of fetuin-A in PCOS girls than healthy was unexpected and could be derived—at least in part—from the status of low-grade inflammation associated with this entity, since it is known that proinflammatory cytokines and proteins such as CRP—which are increased in PCOS—down-regulate fetuin-A expression in the liver.

Whereas in the study by (31) there was no difference between women with PCOS and healthy subjects with regard to fetuin-A levels. Probably, these discrepancies may be related to differences in age and BMI.

SLE

SLE patients have multi-organ involvement related to their chronic inflammatory, autoimmune disease. Calciphtlyaxis and calcinosis are
manifestations of SLE that may be associated with significant morbidity and mortality\(^{(32)}\).

\(^{(33)}\) Found and found no significant difference in fetuin-A level between cases and control. As this cases may evaluated during the relapse remission phase of diseases with suppressed inflammation

**Course of calciphylaxis**

\(^{(34)}\) Found the Fetuin-A inhibits arterial calcification in vitro as it interacts with calcium and phosphorus, increasing their solubility and inhibiting precipitation so prevent calcification

\(^{(19)}\) Found in relatively high concentrations in human blood, and are believed to exert its inhibitory effects on arterial calcification within the bloodstream, blood fetuin-A concentrations represent an attractive candidate marker of arterial calcification

\(^{(35)}\) Found Fetuin-A is a potent regulator of extracellular matrix mineralization and the major serum-based inhibitor of calcium phosphate precipitation. Dysregulation of Fetuin-A levels has been associated with increased systemic inflammation and pro-calcifying cytokine production. Indeed, pro-inflammatory cytokines are considered important promoters of vascular smooth muscle cell osteochondrocytic transformation and mineralization

And \(^{(32)}\) found the Fetuin A, a systemic inhibitor of calcification, facilitates the formation of soluble calcioprotein particles and limits the formation and expansion of hydroxyapatite crystals

**Gender**

In current study, there was negative non-significant correlation between Serum Fetuin A and sex.

In agreement to current study, \(^{(26)}\) did not find any influence of sex on fetuin A. Also, \(^{(36)}\) found Serum fetuin A levels did not correlate significantly with gender which against us. In disagreement with us, a study by \(^{(37)}\) of patients with pseudoxanthoma elasticum, higher fetuin-A levels were determined in women. From here, the authors have been suggested that fetuin-A levels could be changed by gender.

And their study was conducted on different sample size and this may the cause of discrepancy

**Scar**

In current study, there was negative non-significant positive correlation between Serum Fetuin A and Post Acne Scar.

Against our results, in the \(^{(14)}\) study, their results indicate that high levels of fetuin-A may partially contribute to less scar formation in newborn. And this may be the different studied group as they conducted their study on infants.

**BMI**

On the other hand, there was positive non-significant correlation between Serum Fetuin A and BMI.

In agreement with us, according to \(^{(38)}\) there was no significant difference in serum fetuin-A levels between lean and obese subjects so it was not significantly associated with BMI.

Also, \(^{(39)}\) examined the association between circulating fetuin-A levels, and subclinical atherosclerosis in 290 subjects. In all study participants, fetuin-A levels were positively non significantly associated with BMI.

\(^{(36)}\) Studied the relationship between serum fetuin A and clinical diabetes. Serum fetuin A levels did not correlate significantly with body mass index (BMI).

\(^{(26)}\) Did not find any significant influence of BMI on fetuin A.

**Age**

In current study, there was negative non-significant positive correlation between Serum Fetuin A and the age.

In agreement with us, \(^{(36)}\) studied the relationship between serum fetuin A and clinical diabetes. Serum fetuin A levels did not correlate with age. \(^{(26)}\) did not find any influence of age a on fetuin A. As reported by \(^{(31)}\) There was no difference between the groups with regard to Fetuin-A, before and after adjustment for age.

\(^{(27)}\) They could not determine a statistically significant relationship between age and fetuin-A levels and they suggested that age is an ineffective factor on fetuin-A levels in patients with psoriasis.
In contrary, it has been shown previously by\(^{(19)}\) that younger age was strongly associated with higher fetuin-A levels in patients with diabetes mellitus and this difference can be contributed to different diseases studied in their study.

**Severity score**

In current study, there was negative non-significant correlation between Serum Fetuin A and GAGS score. Similar data was reported by\(^{(40)}\) as they found there were no significant correlations among fetuin-A levels and PASI which measured the severity of psoriasis.

\(^{(27)}\) Study revealed that patients with psoriasis were assessed by the PASI score; it was not observed a significant correlation between PASI scores and fetuin-A levels. In contrast,\(^{(41)}\) results showed that fetuin-A levels were significantly correlated with PASI score. Moreover, according to\(^{(25)}\) study, PASI score values were positively correlated with fetuin-A levels. But we found the negative correlation in acne.

**Stress**

In current study, there was negative non-significant correlation between Serum Fetuin A and Stress. Similarly\(^{(42)}\) found there was no significant correlation between fetuin-A levels and stress parameters.

**Smoking**

In current study, there was negative non-significant correlation between Serum Fetuin A and Smoking. Similarly\(^{(43)}\) found no significant correlation was observed between serum fetuin A levels and smoking.

**PIH**

On the other hand, there was positive non-significant correlation between Serum Fetuin A and postinflammatory hyperpigmentation (PIH).

No study evaluated its role and effect on melanine content of skin and postinflammatory pigmentation.

**Conclusion**

Serum fetuin-A levels are detected higher in patients with acne. Also, there are no statistically significant relation between it and gender, age, course of disease and in terms of stress, Sun Exposure, Smoking, Post Acne Scar, Family History, Diet & PIH.

**References**

1. Jahns AC & Alexeyev OA, (2014): Hree-dimensional distribution of Propionibacterium acnes biofilms in human skin. Exp Dermatol 23:687-689.
2. Bhate K, Williams HC(2017); Epidemiology of acne vulgaris. Br J Dermatol;168:474-485.
3. Haukeland JW, Dahl TB, Yndestad A, et al., (2012): Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol. 166:503–510.
4. Sun Q,Cornelis MC, Manson JE, Hu FB, (2013): Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the US. Diabetes.;62:49–55.
5. Bakris GL & Molitch M.(2014): Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care ;37:867–875.
6. Cubukcuoglu T., Rasschaert N., Kacan C., Gul C. and Yavuz M (2013): Relationship between fetuin-A level and cardiovascular risk factors in peritoneal dialysis patients, Turkish Nephrology Dialysis and Transplantation Journal; 22 (1): 78-9.
7. Pateinakis P., Papagianni A., Douma S., et al., (2013): Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients, BMC Nephrology Journal; 14: 122.
8. Gangneux C., Daveau M., Hiron M., et al., (2003): The inflammation induced down regulation of plasma fetuin-A (α2HS-glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighboring binding sites. Nucleic Acid Research Journal; 31(20): 5957-70.

9. Doshi A, Zaheer A and Stiller MJ (1997): A comparison of current acne grading system and proposal of a novel system. Int J Dermatol.;36:416-8.

10. Costa A, Alchorne MMdA and Goldschmidt MCB. (2008): Fatores etiopatogênicos da acne vulgar. Anais brasileiros de dermatología.

11. Tvrzicka E, Kremynda I-S, Stankova B, et al., (2011): FATTY ACIDS AS BIOCOMPONDS: THEIR ROLE IN HUMAN METABOLISM, HEALTH AND DISEASE-A REVIEW. PART 1: CLASSIFICATION, DIETARY SOURCES AND BIOLOGICAL FUNCTIONS. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc 155.

12. Sindhu S, Akhter N, Shenouda S, et al., (2016): Plasma fetuin-A/α2-HS-glycoprotein correlates negatively with inflammatory cytokines, chemokines and activation biomarkers in individuals with type-2 diabetes.

13. Lebreton J, Joisel F, Raoult J, et al. (1979): Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. The Journal of clinical investigation 64: 1118-1129.

14. Wang X-Q, S Hung B, Kempf M, et al., (2009): Fetuin-A promotes primary keratinocyte migration: Independent of epidermal growth factor receptor signalling. Experimental dermatology; 19: e289-292.

15. Li W, Zhu S, Li J, et al. (2011): A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PloS one 6: e16945.

16. Demetriou M, Binkert C, Sukhu B et al., (1996): Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem.; 271: 12755-12761

17. Haasemann M, Nawratil P and Müller-Esterl W. (1991): Rat tyrosine kinase inhibitor shows sequence similarity to human α 2-HS glycoprotein and bovine fetuin. Biochemical journal 274: 899-902.

18. Gousten A-S and Abou-Samra AB. (2011): The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cellular signalling 23: 980-990.

19. Ix JH, Chertow GM, Shlipak MG, et al. (2006): Fetuin-A and kidney function in persons with coronary artery disease—data from the Heart and Soul Study. Nephrology Dialysis Transplantation 21: 2144-2151.

20. Szweras M, Liu D, Partridge EA, et al. (2002): α2-HS glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. Journal of Biological Chemistry 277: 19991-19997.

21. Rochette CN, Rosenfeldt S, Heiss A, et al. (2009): A Shielding Topology Stabilizes the Early Stage Protein–Mineral Complexes of Fetuin- A and Calcium Phosphate: A Time-Resolved Small- Angle X- ray Study. Chembiochem 10: 735-740

22. Wang H and Tracey K. (2002): Fetuin opsonizes macrophage-deactivating cations. Immune Response in the Critically Ill. Springer, 155-163
23. Veas F. (2011): Acute phase proteins: regulation and functions of acute phase proteins; BoD–Books on Demand.
24. Dziegielewksa K, Andersen N and Saunders N. (1998): Modification of macrophage response to lipopolysaccharide by fetuin. *Immunology letters* 60: 31-35.
25. Uysal S, Yilmaz FM, Karatoprak K, et al. (2014): The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis. *Eur Rev Med Pharmacol Sci*;18(22):3453–8.
26. Dziegielewska K, Andersen N and Saunders N. (1998): Modification of macrophage response to lipopolysaccharide by fetuin. *Immunology letters* 60: 31-35.
27. Genc M, Can M, Guven B, et al., (2017): Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis. *Indian J Clin Biochem*; 32: 90-94.
28. Przepiera-Będzak H, Fischer K and Brzosko M. (2016): Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. *International journal of molecular sciences* ;17: 1255.
29. Abali R, Celik C, Tasdemir N, et al., (2013): The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A concentration and carotid intima-media thickness in women with polycystic ovary syndrome. *European Journal of Obstetrics & Gynecology and Reproductive Biology*; 169: 45-49.
30. Díaz M, Gallego-Escured JM, López-Bermejo A, et al., (2018): Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome. *International journal of endocrinology* ;
A Levels with Body Size and Metabolic Phenotypes. *International journal of endocrinology*; 8

40. Uyar B, Akyıldız M, Solak A, et al. (2015): Relationship between serum fetuin-A levels and carotid intima-media thickness in turkish patients with mild to moderate psoriasis. A case-control study. Acta dermatovenerologica Croatica; 23: 171-171.

41. Okan, G., Baki, A. M., Yorulmaz, E., et al., (2016): Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. *Journal of clinical laboratory analysis*; 30(4), 284-289.

42. Sak S, Uyanikoglu H, Incebiyik A, et al. (2018): Associations of serum fetuin-A and oxidative stress parameters with polycystic ovary syndrome. *Clin Exp Reprod Med* 45: 116-121.

43. Oikawa O, Higuchi T, Yamazaki T, et al. (2007): Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. *Clinical and experimental nephrology* 11: 304-308.